Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
Brain Research|January 20, 1992
GFAP expression of human Schwann cells in tissue cultureD Bianchini, I De Martini, A Cadoni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 12, 2013
Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)Y Loriot, D Bianchini, E Ileana, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 25, 2014
Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid useD Lorente, J Mateo, A J Templeton, et al.
Spectrochimica Acta. Part A, Molecular and Biomolecular Spectroscopy|February 27, 2007
Vibrational spectra of silsesquioxanes impregnated with the metallocene catalyst bis(eta(5)-cyclopentadienyl)zirconium(IV) dichlorideD Bianchini, M M Barsan, I S Butler, et al.
British Journal of Cancer|June 29, 2013
Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancerC Pezaro, D Mukherji, N Tunariu, et al.
Clinical Radiology|January 4, 2015
Progressive computed tomography (CT) appearances preceding malignant spinal cord compression (MSCC) in men with castration-resistant prostate cancerC Pezaro, A Omlin, R Perez-Lopez, et al.
European Urology|December 4, 2013
Visceral disease in castration-resistant prostate cancerC Pezaro, A Omlin, D Lorente, et al.
British Journal of Cancer|August 10, 2013
Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancerA Omlin, C J Pezaro, S Zaidi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 2017
Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abirateroneC Massard, J Mateo, Y Loriot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 10, 2018
Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC countsD Lorente, D Olmos, J Mateo, et al.
Pageof 5